(0.32%) 5 116.17 points
(0.38%) 38 386 points
(0.35%) 15 983 points
(-1.31%) $82.75
(6.45%) $2.05
(0.03%) $2 347.80
(-0.24%) $27.47
(3.94%) $958.45
(-0.23%) $0.933
(-0.34%) $10.99
(-0.55%) $0.796
(1.66%) $93.40
Quarter results tomorrow
(bmo 2024-04-30)
Expected move: +/- 10.97%
7.64% $ 15.22
@ $14.92
Ausgestellt: 14 Feb 2024 @ 21:55
Rendite: 2.01%
Vorheriges Signal: Feb 14 - 20:11
Vorheriges Signal:
Rendite: 1.53 %
Live Chart Being Loaded With Signals
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments...
Stats | |
---|---|
Tagesvolumen | 2.35M |
Durchschnittsvolumen | 904 177 |
Marktkapitalisierung | 1.94B |
EPS | $0 ( 2024-02-20 ) |
Nächstes Ertragsdatum | ( $-0.0300 ) 2024-04-30 |
Last Dividend | $0.400 ( 2020-12-17 ) |
Next Dividend | $0 ( N/A ) |
P/E | -21.74 |
ATR14 | $0.0440 (0.29%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-04 | Tetrault Lynn A. | Sell | 6 112 | Common Stock |
2024-02-23 | Stone Warren | Buy | 42 344 | Stock Option (Right to Buy) |
2024-02-23 | Stone Warren | Buy | 25 330 | Performance Stock Unit |
2024-02-23 | Stone Warren | Buy | 25 329 | Restricted Stock Unit |
2024-02-23 | Olivo Alicia C | Buy | 42 344 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
92.19 |
Last 88 transactions |
Buy: 4 083 000 | Sell: 279 791 |
Volumen Korrelation
Neogenomics Inc Korrelation
10 Am meisten positiv korreliert |
---|
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Neogenomics Inc Korrelation - Währung/Rohstoff
Neogenomics Inc Finanzdaten
Annual | 2023 |
Umsatz: | $591.64M |
Bruttogewinn: | $244.60M (41.34 %) |
EPS: | $-0.700 |
FY | 2023 |
Umsatz: | $591.64M |
Bruttogewinn: | $244.60M (41.34 %) |
EPS: | $-0.700 |
FY | 2022 |
Umsatz: | $509.73M |
Bruttogewinn: | $187.90M (36.86 %) |
EPS: | $-1.160 |
FY | 2021 |
Umsatz: | $484.33M |
Bruttogewinn: | $187.06M (38.62 %) |
EPS: | $-0.0700 |
Financial Reports:
No articles found.
Neogenomics Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.400 | 2020-12-17 |
Last Dividend | $0.400 | 2020-12-17 |
Next Dividend | $0 | N/A |
Payout Date | 2020-12-30 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.400 | -- |
Avg. Dividend % Per Year | 0.09% | -- |
Score | 0.55 | -- |
Div. Sustainability Score | 3.17 | |
Div.Growth Potential Score | 0.167 | |
Div. Directional Score | 1.670 | -- |
Year | Amount | Yield |
---|---|---|
2020 | $0.400 | 1.38% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.149 | 1.500 | -2.97 | -4.46 | [0 - 0.5] |
returnOnAssetsTTM | -0.0523 | 1.200 | -1.744 | -2.09 | [0 - 0.3] |
returnOnEquityTTM | -0.0921 | 1.500 | -2.13 | -3.20 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 6.20 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 5.67 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 3.56 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.364 | -1.500 | 3.94 | -5.90 | [0 - 0.6] |
interestCoverageTTM | 20.01 | 1.000 | 3.70 | 3.70 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.0155 | 2.00 | -0.00517 | -0.0103 | [0 - 30] |
freeCashFlowPerShareTTM | -0.244 | 2.00 | -0.122 | -0.244 | [0 - 20] |
debtEquityRatioTTM | 0.650 | -1.500 | 7.40 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.413 | 1.000 | 6.44 | 6.44 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.174 | 1.000 | -5.48 | -5.48 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.00319 | 1.000 | -1.129 | -1.129 | [0.2 - 2] |
assetTurnoverTTM | 0.352 | 0.800 | -0.987 | -0.790 | [0.5 - 2] |
Total Score | 3.17 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -20.24 | 1.000 | -2.15 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0921 | 2.50 | -1.372 | -3.20 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.244 | 2.00 | -0.0813 | -0.244 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.0155 | 2.00 | -0.00517 | -0.0103 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 2.32 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.00330 | 1.000 | -2.58 | 0 | [0.1 - 0.5] |
Total Score | 0.167 |
Neogenomics Inc
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.